CEA、CA125和NSE联合检测在肺癌诊治中的应用  

Clinical Application of Combined Determination of CEA,CA125 and NSE in the Diagnosis of Lung Cancer

作　　者：保勇[1] 余坷[1] 喻华[2] 赵豫琴[1] 

机构地区：[1]成都市第二人民医院核医学科,四川成都610017 [2]四川省医学科学院,四川省人民医院检验科,四川成都610072

出　　处：《标记免疫分析与临床》2008年第1期14-16,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：为探讨CEA、CA125和NSE三种肿瘤标志物联检在肺癌诊治中的应用及同时测定胸水与血清中三者的水平在肺癌诊断中的差异,采用化学发光免疫分析法分别测定58例肺癌、37例肺良性疾病患者血清和胸水中CEA、CA125和NSE水平。结果显示,肺癌患者胸水中CEA为60.6±23.5ng/mL,CA125为243.4±120.5U/mL,NSE为33.4±24.5ng/mL,显著高于本组血清中(P<0.01)和肺良性疾病组的血清或胸水中的水平(P<0.01)。胸水中三项标志物对肺癌的敏感性分别为67.2%、70.7%、55.2%,而血清中相对应的为51.7%、65.5%、41.4%。胸水中三项联检对肺癌的敏感性达87.1%,而对应的血清中三项联检对肺癌的敏感性则为81.0%。联合检测CEA、CA125和NSE三项标志物可提高肺癌诊断的敏感性,对诊断和鉴别诊断良、恶性胸水有重要临床价值,测定胸水标志物比血清更有意义。To explore the clinical value of combined determination of serum and pleural effusion CEA, CA125 and NSE levels in the diagnosis of lung cancer, the serum and pleural effusion CEA, CA125 and NSE levels were detected in 58 patients with lung cancer and 37 patients with benign lung diseases by chemiluminescence immunoassay. The results showed that the levels of CEA, CA125 and NSE in pleural effusion were 60.6±23.5 ng/mL, 243.4±120.5 U/mL and 33.4±24.5ng/mL respectively in patients with lung cancer, they were significantly higher than those in serum in benign lung diseases （P〈0.01）. The sensitivity of CEA, CA125 and NSE in pleural effusion with lung cancer were 67.2%, 70.7% and 55.2% respectively, but the sensitivity in serum were 51.7% ,65.5% and 41.4% respectively. The sensitivity of combined determination of these three markers pleural effusion and serum was 87.1% and 81.0% respectively. The combined determination of CEA, CA125 and NSE could significantly improve the sensitivity and specificity of the diagnosis of lung cancer. The determination of these three markers in pleural effusion was more significant than that of in serum.

关 键 词：癌胚抗原 糖类抗原125 神经特异性烯醇化酶 肺癌 

分 类 号：R734.2[医药卫生—肿瘤]